PK/PD and Bioanalytical Considerations of AAV-Based Gene Therapies: an IQ Consortium Industry Position Paper
Uma Kavita(Spark Therapeutics (United States)), Nagendra Chemuturi(Moderna Therapeutics (United States)), Karelle Ménochet(UCB Pharma (United Kingdom)), Wibke Lembke, LiNa Loo(Vertex Pharmaceuticals (United States)), John Kamerud(Pfizer (United States)), Vibha Jawa(Bristol-Myers Squibb (Germany)), Wei Gao(National Earthquake Response Support Service), Kay‐Gunnar Stubenrauch(Roche Pharma AG (Germany)), Christopher M. Wiethoff(Eli Lilly (United States)), Manuela Braun(Bayer (Germany)), Adam Vigil(Boehringer Ingelheim (United States)), Xiaodong Fang(BGI Group (China)), Michael Z. Liao(Kaiser Permanente South San Francisco Medical Center), Kefeng Sun(Takeda (United States)), Tong‐Yuan Yang(Janssen (United States)), Magdalena Hofer(Spark Therapeutics (United States)), Fraser McBlane(Novartis (Switzerland)), Xu Zhu(AstraZeneca (United States)), Cindy Q. Xia(Takeda (United States)), Hardik Mody(Kaiser Permanente South San Francisco Medical Center), Vijay Upreti(Amgen (United States)), Inka V. Braun(Bayer (Germany)), Swati Gupta(AbbVie (United States))
Cited by 17
Related Papers
A global reference for human genetic variation
|Nature|2015|19.9k
The diploid genome sequence of an Asian individual
|Nature|2008|960
Genome sequencing and comparison of two nonhuman primate animal models, the cynomolgus and Chinese rhesus macaques
|Nature Biotechnology|2011|321
A Clostridia-rich microbiota enhances bile acid excretion in diarrhea-predominant irritable bowel syndrome
|Journal of Clinical Investigation|2019|190